

Valeant To Participate At The Evercore ISI Biopharma Catalyst/Deep Dive Conference

November 21, 2017

LAVAL, Quebec, Nov. 21, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Paul S. Herendeen, executive vice president, Finance, and chief financial officer, and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Evercore ISI Biopharma Catalyst/Deep Dive Conference in Boston on Nov. 29, 2017 at 11:00 a.m. EST.

A live webcast and audio archive of the event will be available on the Investor Relations page of the Valeant web site at:

<http://ir.valeant.com/events-and-presentations/2017>

About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com

Investor Contact:

Arthur Shannon

arthur.shannon@valeant.com

(514) 856-3855

(877) 281-6642 (toll free)

Media Contact:

Lainie Keller

lainie.keller@valeant.com

(908) 927-0617

View original content with multimedia:

<http://www.prnewswire.com/news-releases/valeant-to-participate-at-the-evercore-isi-biopharma-catalystdeep-dive-conference-300558427.html>

SOURCE Valeant Pharmaceuticals International, Inc.



Investor Inquiries

ir@bauschhealth.com

877-281-6642

514-856-3855 (Canada)

Media inquiries

Corporate.communications@bauschhealth.com

908-569-3692

[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.
©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION

